At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
Alogliptin +2 moredrug
Likely dose
Alogliptin 12.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects
In Brief
A Phase 1 clinical trial evaluating Alogliptin for Pharmacokinetics and Pharmacodynamics. Completed, enrolled 48 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics and Pharmacodynamics
CountriesSouth Korea
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionSep 2011
TodayJul 2026
First PostedJul 12, 2011
Enrollment StartJul 1, 2011
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.0 years ago
Interventions
Alogliptindrug
Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
Alogliptindrug
Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
Alogliptindrug
Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.